MedTrace Logo

3Sm Challenge Model Protocol

NCT04753892 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-07-27

No results posted yet for this study

Summary

The 3Sm challenge study is a small clinical study in eight healthy volunteers who will be injected with a protein which includes a short portion ('3Sm peptide') which is derived from a part (the '3S region') of the coat protein of HIV. The researchers believe that the 3Sm peptide might trigger an immune response which includes rare antibodies able to neutralise a wide range of different strains of HIV. The results will be useful in guiding the development of future vaccines against HIV, and other diseases.

Conditions

  • Healthy

Interventions

OTHER

3SM2-G-CRM197 with squalene adjuvant

Immune challenge agent

Sponsors & Collaborators

  • Minka Therapeutics

    collaborator UNKNOWN

  • ANRS, Emerging Infectious Diseases

    collaborator OTHER_GOV

  • Imperial College London

    lead OTHER

Principal Investigators

  • Katrina Pollock, MD · Imperial College London

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2022-07-20
Completion
2022-07-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04753892 on ClinicalTrials.gov